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Abstract
Background and Aims: Anti-HER-2 antibodies targeting distinct epitopes have different biological functions on
cancer cells. In a previous study, we demonstrated that anti-HER-2 engineering antibody ChA21 was able to bind
to subdomain I of HER-2 extracellular domain. In this study, The effects of ChA21 on growth and apoptosis against
ovarian carcinoma cell SK-OV-3 over-expressing HER-2 in vitro and in vivo were investigated.
Methods: Cell growth inhibition was evaluated by MTT assay. Apoptosis was detected by TUNEL stain,
transmission electron microscopy and flow cytometry on cultured cells and tissue sections from nude mice
xenografts. The apoptosis-related proteins Bax and Bcl-2 were assessed by immunohistochemistry.
Results: We found that treatment of ChA21 caused a dose-dependent decrease of cell proliferation in vitro and a
significant inhibition of tumor growth in vivo. ChA21 therapy led to a significant increase in the induction of
apoptosis, and up-regulated the expression of Bax, while the expression of Bcl-2 was down-regulated.
Conclusion: These data suggest that ChA21 inhibits the growth and induces apoptosis of SK-OV-3 via regulating
the balance between Bax and Bcl-2.
Introduction
Ovarian cancer is the most frequent cause of death
among all gynecologic cancer patients [1], and there are
currently no effective therapeutic approaches for the dis-
ease in spite of advances in surgery, chemotherapy, and
radiotherapy [2,3]. Hence, the effective treatment for
ovarian cancer is urgently needed.
HER-2, also named neu/c-erbB-2, is a key member of
the epidermal growth factor receptor (EGFR) family,
which comprises an extracellular domain (ECD) with
four subdomains (I/L1, II/S1, III/L2, and IV/S2), a single
transmembrane domain, and an intracellular tyrosine
kinase domain [4,5]. The aberrant activity of HER-2 has
been shown to play a key role in the development and
growth of tumor cells [6,7]. HER-2 gene over-expressed
in ovarian cancer has been reported to be approximately
15-30% [8,9]. HER-2 over-expression in human carci-
noma tissues does relate with the poor prognosis but
provide the fundamental rationale for the development of
immunotherapy to target HER-2. The most attractive
humanized antibody against HER-2 is Herceptin [10,11],
which blocks HER-2 dimerization and induces apoptosis
[12]. It has been used as an agent in first-line treatment
of HER-2 over-expressing breast cancer by binding to
HER-2 extracellular domain in subdomain IV [13,14]. It
was also reported that Herceptin appeared to be a candi-
date as a treatment modality for HER-2 over-expressing
ovarian cancer [15]. ChA21 is an engineered anti-HER-2
antidbody that is prepared by the surface epitope mask-
ing (SEM) method, wherein recognized epitopes are
mainly located in subdomain I of the HER-2 extracellular
domain [16-18].
In previous study, we reported the preparation of an
anti-HER-2 monoclonal antibody(MAb) muA21 and
found that it could inhibit the growth of the human
breast cancer SK-BR-3 cells [19,20]. Subsequently, we
cloned the genes of variant regions of this monoclonal
antibody, constructed the single-chain Fv (scFv) anti-
body, and further constructed a chimeric scFv-Fc engi-
neered antibody ChA21 [16]. After that, we constructed
a molecular model of Ag-Ab complex based on the crys-
tal structures of the ChA21 scFv and HER-2 ECD, and
found that ChA21 recognized epitopes mainly located in
subdomain I [18]. In the present study, we hypothesized
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growth inhibition of HER-2 over-expressed SK-OV-3
cells and induction of apoptosis as Herceptin binds to
subdomain IV.
Materials and methods
Cell line
The HER-2 overexpressing human ovarian cancer cells
S K - O V - 3[ 2 1 ]w e r eo b t a i n e df r o mt h eC e l lB a n ko f
Shanghai Institutes for Biological Sciences (Shanghai,
China). They were cultured in DMEM (Gibco, USA)
supplemented with 10% FBS (Gibco, USA) in an incuba-
tor with 5% CO2 and saturated humidity at 37°C.
MTT assay
SK-OV-3 (5 × 10
3 per well) cells were seeded in 96-well
plates and cultured overnight. Then, the medium was
replaced with fresh DMEM or the same medium con-
taining ChA21 (prepared as described in previous stu-
dies [16,17]) at concentrations of 0.067, 0.2, 0.6, 1.8,
5.4 μg/ml for 72 h, or the cells were treated with ChA21
at the concentration of 5.4 μg/ml for 24, 48, 72, 96 h,
respectively. MTT (Sigma, USA) with 20 μl samples was
added to each well and incubated for an additional
4 h. Then culture medium was discarded and 150 μl
dimethyl sulfoxide (DMSO) was added. OD 570 nm was
measured by a multi-well scanning spectrophotometer
(Multiskan MK3, Finland). The inhibitory growth rate
was calculated as follows: (1 - experimental OD value/
control OD value) × 100%.
Inhibition of ChA21 on SK-OV-3 nude mice xenografts
BALB/c female nude mice (6 weeks old, 18.0 ± 2.0 g)
were obtained from Shanghai Laboratory Animal Center
(SLAC, China). SK-OV-3 cells (5 × 10
6 per mouse) were
subcutaneously inoculated into the left flank of the
mice. Tumor-bearing mice in which the tumor volume
reached about 50 mm
3 were selected, and randomized,
injected with either sterile normal saline or ChA21
(40 mg/kg) twice weekly via caudal vein (i.v) for
5 weeks. Tumor size was measured twice a week and
converted to tumor volume (TV) as the following for-
mula: TV (mm
3)=( a×b
2)/2, where a and b are the lar-
gest and smallest diameters (in millimeters), respectively.
All animals were killed after giving ChA21 or sterile
normal saline for 5 weeks, and the transplantation
tumors were removed, weighed and fixed for further
study. The tumor inhibition ratio (TIR) was calculated
as follows: (1 - experimental mean weight/control mean
weight) × 100% [22].
Evaluation of potential adverse effects
To evaluate the potential side effects or toxicity on mice
during treatment of ChA21, g r o s sm e a s u r e ss u c ha s
weight loss, ruffling of fur, life span, behavior, and feed-
ing were investigated. The tissue of heart, liver, spleen,
lung, kidney, and brain were fixed in 10% neutral buf-
fered formalin solution and embedded in paraffin, and
then stained with H&E.
Transmission electron microscopy
SK-OV-3 cells treated with ChA21 (5.4 μg/ml) for 72 h,
as well as 1 mm × 1 mm tumor tissues from nude mice,
were fixed with glutaraldehyde and osmium tetroxide.
After dehydration in a graded series of acetone and
steeping in propyleneoxide, the samples were ultrami-
crotomed after embedded in Epon 812. The sections
were stained with lead citrate, and examined by an elec-
tron microscope (JEM-1230, Japan).
TUNEL staining of apoptotic cells
SK-OV-3 cells (2.5 × 10
4 per well) were seeded in 24-
well plates with coverslips, and cultured in the medium
with 5.4 μg/ml ChA21 for 72 h. Then, the coverslips
were taken out, washed, fixed, and stained according to
the instruction manual of in situ cell-death detection
kits (Roche). The tissue sections from nude mice xeno-
grafts were dewaxed and hydrated, and then were incu-
bated with 20 μg/L proteinase K at room temperature
for 15 min, followed by incubation with TUNEL reac-
tion mixture. Converter-peroxidase solution was added
for further incubation. Labeled nuclei were demon-
strated using 3, 3’-diaminobenzidine and counterstained
with hematoxylin. Four equal-sized fields were randomly
chosen and analyzed, the apoptotic index (AI) was
defined as follows: AI (%) = 100 × apoptotic cells/total
tumor cells.
Propidium iodide staining of dead cells for flow
cytometry
SK-OV-3 cells were incubated with ChA21 (0.2 or 5.4 μg/
ml) for 72 h, harvested and counted, and 1 × 10
6 cells
were resuspended in 100 μl phosphate-buffered saline
(PBS). Then, 5 μl of propidium iodide (PI, Beckman,
USA) was added, incubated for 30 min at room tempera-
ture in dark. Then the cells were subjected to flow cyto-
metry to measure the death rate (%) with a Beckman
Coulter Epics-XL-MCL cytometer (California, USA).
Immunohistochemical and immunocytochemical staining
for Bcl-2 and Bax
The SK-OV-3 cells were cultured and fixed as
described above in TUNEL staining. The sections of
paraffin-embedded tissue were dewaxed and rehy-
drated. After inactivating endogenous peroxidase with
3% H202, and blocking cross-reactivity with normal
serum, the sections were incubated overnight at 4°C
with the Bcl-2 antibody (1:150, Santa Cruz, California,
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nia, USA), respectively. Then, the sections were treated
with streptoavidin-peroxidase reagent (Zymed, USA),
and the peroxidase label was demonstrated using 3, 3’-
diaminobenzidine, counterstained with hematoxylin.
Omission of the primary antibody was used as negative
control. The immunostained sections were examined
by using an Eclipse E800 microscope (Nikon, Japan)
coupled to a digital camera. The mean optical density
(MOD) of microscopic images was quantitatively ana-
lyzed by Image-pro Plus 5.02 (Media Cybernetics Inc,
USA).
Statistical analysis
Data were expressed as mean ± standard deviation ( 
± s). Comparison between groups was made by the
Independent Samples t-test, P < 0.05 was considered
statistically significant.
Results
ChA21 inhibits the growth of SK-OV-3 cells in vitro and in
vivo
To evaluate the effect of ChA21 on cell proliferation,
human ovarian cancer cells SK-OV-3 were treated with
different doses (0.067-5.4 μg/ml) of ChA21 for 72 h or
treated with ChA21 (5.4 μg/ml) for 24, 48, 72, 96 h,
respectively. As shown in Fig. 1A, treatment of ChA21
resulted in a dose-dependent inhibition of SK-OV-3 cell
proliferation by MTT assay; the growth inhibitory rates
were 5.85, 10.92, 16.55, 23.87 and 35.33% at the corre-
sponding concentrations of 0.067, 0.2, 0.6, 1.8 and 5.4
μg/ml, respectively. As shown in Fig. 1B, treatment of
Figure 1 ChA21 inhibits the growth of SK-OV-3 cells in vitro and in vivo. (A) Cells were exposed to 0.067-5.4 μg/ml ChA21 for 72 h. (B)
Cells were treated with ChA21 at the concentration of 5.4 μg/ml for 24, 48, 72, 96 h, respectively. OD 570 nm was measured by a multi-well
scanning spectrophotometer. Significant differences are represented by asterisk (P < 0.05) and double asterisk (P < 0.01). (C, D) Female BALB/c
nude mice were subcutaneously inoculated with human ovarian cancer cells SK-OV-3 (5 × 10
6) into the left flank of mice. The mice were
randomized and injeceted twice weekly via caudal vein with either sterile normal saline or ChA21 (40 mg/kg) for 5 weeks. Tumor size was
measured twice a week and converted to tumor volume. ChA21 treatment group have a significantly reduced tumor volume compared with
the controls (P < 0.05). Results are representative of the mean ± s.e.m. of 8 animals in each group.
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SK-OV-3 cells, the growth inhibitory rates were 14.78,
22.89, 34.43 and 39.85% at the corresponding times of
24, 48, 72, 96 h.
Female BALB/c nude mice were subcutaneously
inoculated with human ovarian cancer cells SK-OV-3 (5
×1 0
6) into the left flank of mice. The mice were rando-
mized and injected twice weekly via caudal vein with
either sterile normal saline or ChA21 (40 mg/kg) for 5
weeks. As shown in Fig. 1C, D, the tumor volume
(mm
3) in the control group grew remarkably fast, reach-
ing 1664.5 ± 1028.7 after 35 days injection. In contrast,
the tumor volume (mm
3) of mice treated with ChA21
was significantly (P < 0.05) smaller than the controls,
reaching only 813.6 ± 724.8. The mean weight (g) of the
transplantation tumors in ChA21 treatment group was
0.78 ± 1.14, which also significantly (P < 0.05) decreased
as compared to that in the controls (1.24 ± 0.94). In
addition, the tumor inhibition ratio reached 37.1%.
Observation of Potential Toxicity
To evaluate the possible adverse effects of the treat-
ments, weight of mice was monitored every 3 days
throughout the whole experiment and considered a vari-
able for evaluation of systemic well-being or cachexia.
No significant differences in weights were found
between the two groups. No adverse consequences in
other gross measures such as ruffling of fur, behavior,
feeding, or toxic death were observed. In the histopatho-
logical examination of the heart, liver, spleen, lung, kid-
ney and brain, no significant injuries were found after 5
weeks injection (data not shown).
ChA21 induces apoptosis of SK-OV-3 cells in vitro and in
vivo
Using transmission electron microscopy, we discerned
the ultrastructural changes of SK-OV-3 cells induced by
ChA21. After treatment of ChA21 (5.4 μg/ml) for 72 h
or the tumor tissues removed from nude mice treated
ChA21 (40 mg/kg) for 5 weeks, a large number of cells
presented a series of ultrastructural changes such as
chromatin condensation, chromatin crescent, and
nucleus fragmentation (Fig. 2B, D), all of which were
characteristics of cells undergoing apoptosis. On the
contrary, control cells were morphologically normal and
exhibited no signals of apoptosis (Fig. 2A, C).
Cells cultured on coverslips and tissue sections from
t h ea b o v ee x p e r i m e n t sw e r es t a i n e dw i t ht h eT U N E L
agent, and examined by microscopy. Less apoptotic cells
were detected in the control group, whereas more apop-
totic cells were detected in ChA21 treatment group (Fig.
3). The apoptotic cells on coverslips and tissue sections
were counted to calculate the apoptotic index. In vitro,
the AI value in ChA21 (5.4 μg/ml) treatment group
Figure 2 Transmission electron microscopy observation.A f t e rC h A 2 1( 5 . 4μg/ml) treatment for 72 h or the tumor tissues removed from
nude mice treated ChA21 (40 mg/kg) for 5 weeks, a large number of cells presented a series of ultrastructural changes of apoptosis (B, D). On
the contrary, control cells were morphologically normal and exhibited no signals of apoptosis (A, C). (magnification: A, C × 3000; B, D × 8000).
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controls (6.22 ± 1.09, P < 0.05). In vivo, the AI value in
ChA21 (40 mg/kg) treatment group reached 9.16 ± 2.44,
which was also higher than that in the controls (3.45 ±
0.98, P < 0.05).
SK-OV-3 cells were incubated with ChA21 (0.2 or 5.4
μg/ml) for 72 h, and flow cytometric analysis was used
to measure the death rate. As shown in Fig. 4, there was
a significant difference between ChA21 group and con-
trol group in the death rate (%) (P < 0.05). After the
treatment of SK-OV-3 cells with ChA21 (0.2 or 5.4 μg/
ml) for 72 h, the death rate (%) reached 8.75 ± 0.97, and
19.73 ± 1.99, respectively.
Expression of Bcl-2 and Bax
Detection of the expression of apoptosis-related proteins
of Bcl-2 and Bax by immunohistochemistry showed that
ChA21 therapy could up-regulate the expression of Bax,
and down-regulate the expression of Bcl-2 (Fig. 5),
thereby reducing the ratio of Bcl-2/Bax in vitro and in
vivo. As shown in Fig. 6, MOD values of Bax in ChA21
group were higher than those in control group (P <
0.05), while MOD values of Bcl-2 and the ratio of Bcl-2
to Bax were lower (P < 0.05) both in vitro and in vivo.
Discussion
In recent years, a number of monoclonal antibodies
(MAb) have been developed against HER-2 ECD, such
as 4D5 (Herceptin, trastuzumab) and 2C4 (Pertuzumab)
[10,23]. Herceptin is a humanized recombinant MAb
that was first approved by the U.S. FDA for use in HER-
2 over-expressing metastatic breast cancer. Current stu-
dies show that it appears to be a candidate as a treat-
ment modality for HER-2 over-expressing ovarian
cancer as well [24]. However, more studies in clinical
application showed that there is an increased incidence
of serious cardiac events, particularly when Herceptin
was administered in combination with anthracyclines
[25,26], and pulmonary complications also had been
reported [27]. Patients who have had a significant
Figure 3 ChA21 induces apoptosis of SK-OV-3 cells in vitro and in vivo by TUNEL staining. (A): Control group in vitro (B): ChA21 (5.4 μg/
ml) group in vitro (C): Control group in vivo (D): ChA21 (40 mg/kg) group in vivo. Cells cultured with coverslips and tissue sections were stained
with the TUNEL agent and examined by light microscopy. Less apoptotic cells were detected in control group, whereas more apoptotic cells
were detected in ChA21 treatment group. (magnification: × 200)
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started to appear the drug resistant [28,29]. Moreover,
according to the surveyed data about the clinical thera-
peutic effect of Herceptin, the therapeutic effective rate
of Herceptin treated alone to patients with HER-2 over-
expressed only reached 12-14% [30]. These results urge
people to conduct more researches, regarding the
mechanism of antibodies curing the neoplasms, and
develop novel humanized recombinant MAb for HER-2.
Therefore, three strains of murine MAb A18, A21,
and A22, which direct against HER-2 ECD were devel-
oped, and MAb A21 was found to specifically inhibit
the growth of HER-2 over-expressing cells [20]. To
reduce the potential for generating a human anti-mouse
immune response, Murine MAb A21 was humanized to
develop an anti-HER-2 engineering antidbody, ChA21
[16,17]. In previous study, we constructed a molecular
model of Ag-Ab complex based on the crystal structures
of the ChA21 scFv and HER-2 ECD [18]. Unlike Her-
ceptin that binds to subdomain IV, ChA21 recognizes
epitopes that are mainly located in subdomain I. It is
possible, that anti-HER-2 antibodies targeting distinct
epitopes have different biological functions on cancer
cells with different mechanisms [31].
Thus, in the present study, we confirmed that ChA21
binding to subdomain I could inhibit the growth and
induce apoptosis of HER-2 over-expressing human ovar-
ian cancer cells SK-OV-3 in vitro and in vivo.T h e
results showed that in vitro, the cell growth was signifi-
cantly inhibited by ChA21 in a dose- and time-depen-
dent manner. Likewise, ChA21 (40 mg/kg) inhibited the
growth of SK-OV-3 cells in vivo with the tumor inhibi-
tion ratio of 37.1%. It is known that apoptosis is the
programmed death of cells, a variety of studies have
Figure 4 ChA21 induces death of SK-OV-3 cells in vitro with PI staining. SK-OV-3 cells were incubated with ChA21 (0.2 or 5.4 μg/ml) for 72
h, and flow cytometric analysis was used to measure the death rate. Significant differences in death rates are represented by asterisk (P < 0.05)
and double asterisk (P < 0.01).
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not only the cause of the over growth but also the loss
of natural apoptosis [32,33]. Therefore, the antibody
that is capable of inducing cancer cells apoptosis would
be helpful for cancer treatment. In this study, transmis-
sion electron microscope, TUNEL staining and flow
cytometry were used to detect apoptosis, and the results
demonstrated that ChA21 could induce apoptosis on
SK-OV-3 cells both in vitro and in vivo. Hence, we can
deduce that the growth inhibition of ChA21 on SK-OV-
3 cells was at least partially contributed by its role of
apoptosis induction. To further investigate the possible
molecular mechanism of apoptosis induced by ChA21,
apoptosis-regulated proteins Bcl-2 and Bax were
detected by immunocytochemistry and immunohisto-
chemistry. It is known that Bcl-2 gene acts to inhibit
apoptosis, while Bax gene induces apoptosis. The imbal-
anced expression of Bcl-2 to Bax protein influences the
Figure 5 Expression of Bcl-2 and Bax as detected by immunohistochemistry. Detection of the expression of apoptosis-related proteins of
Bcl-2 and Bax showed that ChA21 therapy could upregulate the expression of Bax and downregulate the expression of Bcl-2 in vitro and in vivo.
Figure 6 The MOD values on expression of Bcl-2 and Bax. MOD values of Bax in ChA21 treatment group were higher than those in the
control group (P < 0.05), while MOD values of Bcl-2 and the ratio of Bcl-2 to Bax were lower (P < 0.05) both in vitro and in vivo. (magnification:
in vitro × 400; in vivo × 200).
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nal factors [34,35]. Recent s t u d i e sr e p o r t e dt h a tH E R - 2
over-expression is accompanied by up-regulation of Bcl-
2 and down-regulation of Bax [36,37]. Our results
showed that after exposure to ChA21, Bcl-2 expression
of SK-OV-3 cells was decreased, and Bax expression
was increased, resulting in a decrease in Bcl-2/Bax
value. Therefore, we concluded that one of the pathways
of ChA21 inducing apoptosis might up-regulate Bax
expression, and down-regulate Bcl-2 expression.
In conclusion, the results indicate that ChA21 could
inhibit growth and induce apoptosis of human ovarian
cancer cell line SK-OV-3 via regulating the balance
between Bax and Bcl-2. It suggests that ChA21 might be
a new promising candidate in the treatment of HER-2
over-expressed ovarian cancers. In addition, the
mechanisms of ChA21 inhibits SK-OV-3 cells growth
not only via inducing apoptosis, but also by interfering
with HER-2 heterodimerization and affecting HER-2 sig-
naling pathway, and further study is needed.
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